Pharmacokinetics of pioglitazone after multiple oral dose administration in horses

Journal of Veterinary Pharmacology and Therapeutics

Volumn 34, Issue 3, 2011, Pages 252-258

  Wearn, J M G ^a   Crisman, M V ^a   Davis, J L ^b   Geor, R J ^c,d   Hodgson, D R ^a   Suagee, J K ^c   Ashraf Khorassani, M ^c   McCutcheon, L J ^a,d  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HORSE; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HORSES; HYPOGLYCEMIC AGENTS; TABLETS; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES;

EQUIDAE;

EID: 79960160020     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01217.x     Document Type: Article

References (29)

1. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J.W., Mathisen, A.L. & Schneider, R.L. (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23, 1605-1611.
2. Asplin, K.E., Sillence, M.N., Pollitt, C.C. & McGowan, C.M. (2007) Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies. Veterinary Journal, 174, 530-535.
3. Berger, J.P., Petro, A.E., Macnaul, K.L., Kelly, L.J., Zhang, B.B., Richards, K., Elbrecht, A., Johnson, B.A., Zhou, G., Doebber, T.W., Biswas, C., Parikh, M., Sharma, N., Tanen, M.R., Thompson, G.M., Ventre, J., Adams, A.D., Mosley, R., Surwit, R.S. & Moller, D.E. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Molecular Endocrinology, 17, 662-676.
4. Budde, K., Neumayer, H.H., Fritsche, L., Sulowicz, W., Stompor, T. & Eckland, D. (2003) The pharmacokinetics of pioglitazone in patients with impaired renal function. British Journal of Clinical Pharmacology, 55, 368-374.
5. Christensen, M.L., Meibohm, B., Capparelli, E.V., Velasquez-Mieyer, P., Burghen, G.A. & Tamborlane, W.V. (2005) Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. Journal of Clinical Pharmacology, 45, 1137-1144.
6. Davis, J.L., Little, D., Blikslager, A.T. & Papich, M.G. (2006) Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. Journal of Veterinary Pharmacology and Therapeutics, 29, 379-385.
7. Eckland, D. & Danhof, M. (2000) Clinical pharmacokinetics of pioglitazone. Experimental and Clinical Endocrinology and Diabetes, 108 (Suppl. 2), S234-S242.
8. Frank, N. (2009) Equine metabolic syndrome. Journal of Equine Veterinary Science, 29, 259-267.
9. Geor, R.J. (2008) Metabolic predispositions to laminitis in horses and ponies: obesity, insulin resistance and metabolic syndromes. Journal of Equine Veterinary Science, 28, 753-759.
10. Geor, R. & Frank, N. (2009) Metabolic syndrome-From human organ disease to laminar failure in equids. Veterinary Immunology and Immunopathology, 129, 151-154.
11. Hoffman, R.M., Boston, R.C., Stefanovski, D., Kronfeld, D.S. & Harris, P.A. (2003) Obesity and diet affect glucose dynamics and insulin sensitivity in Thoroughbred geldings. Journal of Animal Science, 81, 2333-2342.
12. Hustace, J.L., Firshman, A.M. & Mata, J.E. (2009) Pharmacokinetics and bioavailability of metformin in horses. American Journal of Veterinary Research, 70, 665-668.
13. Ikeda, H., Taketomi, S., Sugiyama, Y., Shimura, Y., Sohda, T., Meguro, K. & Fujita, T. (1990) Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittel-Forschung, 40 (2 Pt), 156-162.
14. Johnson, P.J. (2002) The equine metabolic syndrome peripheral Cushing's syndrome. Veterinary Clinics of North America. Equine Practice, 18, 271-293.
15. Kalliokoski, A., Neuvonen, M., Neuvonen, P.J. & Niemi, M. (2008) No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British Journal of Clinical Pharmacology, 65, 78-86.
16. Lu, L., Reiter, M.J., Xu, Y., Chicco, A., Greyson, C.R. & Schwartz, G.G. (2008) Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia, 51, 675-685.
17. Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L.J. & DeFronzo, R.A. (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care, 24, 710-719.
18. Rangwala, S.M. & Lazar, M.A. (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends in Pharmacological Sciences, 25, 331-336.
19. Rosenblatt, S., Miskin, B., Glazer, N.B., Prince, M.J. & Robertson, K.E. (2001) The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coronary Artery Disease, 12, 413-423.
20. Scheen, A.J. (2001) Thiazolidinediones and liver toxicity. Diabetes Metab, 27, 305-313.
21. Shen, Z., Reed, J.R., Creighton, M., Liu, D.Q., Tang, Y.S., Hora, D.F., Feeney, W., Szewczyk, J., Bakhtiar, R., Franklin, R.B. & Vincent, S.H. (2003) Identification of novel metabolites of pioglitazone in rat and dog. Xenobiotica, 33, 499-509.
22. Sugiyama, Y., Shimura, Y. & Ikeda, H. (1990a) Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneimittel-Forschung, 40, 436-440.
23. Sugiyama, Y., Taketomi, S., Shimura, Y., Ikeda, H. & Fujita, T. (1990b) Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneimittel-Forschung, 40, 263-267.
24. Treiber, K., Carter, R., Gay, L., Williams, C. & Geor, R. (2009) Inflammatory and redox status of ponies with a history of pasture-associated laminitis. Veterinary Immunology and Immunopathology, 129, 216-220.
25. Wang, M. & Miksa, I.R. (2007) Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 856, 318-327.
26. Willson, T.M., Lambert, M.H. & Kliewer, S.A. (2001) Peroxisome proliferator-activated receptor gamma and metabolic disease. Annual Review of Biochemistry, 70, 341-367.
27. Yamasaki, Y., Kawamori, R., Wasada, T., Sato, A., Omori, Y., Eguchi, H., Tominaga, M., Sasaki, H., Ikeda, M., Kubota, M., Ishida, Y., Hozumi, T., Baba, S., Uehara, M., Shichiri, M. & Kaneko, T. (1997) Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku Journal of Experimental Medicine, 183, 173-183.
28. Yki-Jarvinen, H. (2004) Thiazolidinediones. New England Journal of Medicine, 351, 1106-1118.
29. Zhou, R., Bruns, C.M., Bird, I.M., Kemnitz, J.W., Goodfriend, T.L., Dumesic, D.A. & Abbott, D.H. (2007) Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys. Reproductive Toxicology, 23, 438-448.